GlassScriptPhysician profile
Laura L Harbison
NPI 1427239318
$1,425.03
in general payments reported to CMS, 2019-2025
26 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.31 · 2020: $177 · 2021: $155 · 2022: $51.03 · 2023: $268 · 2024: $245 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $185.02 | 2023-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $156.93 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $114.87 | 2020-2025 | Airsupra, Flumist Quadrivalent |
| Pfizer INC. | $107.91 | 2020-2025 | |
| Mylan Specialty L.P. | $86.10 | 2019-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $72.42 | 2020-2023 | Xarelto |
| Glaxosmithkline, LLC. | $71.99 | 2021-2025 | Bexsero, Rotarix, Shingrix |
| Merck Sharp & Dohme LLC | $63.68 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Baudax Bio INC. | $62.63 | 2020-2022 | |
| Sanofi Pasteur INC. | $58.95 | 2019-2025 | |
| Novo Nordisk INC | $53.69 | 2024-2025 | Rybelsus, Wegovy, Ozempic |
| Ferring Pharmaceuticals INC. | $49.41 | 2023 | Rebyota |
| Organon LLC | $39.42 | 2023-2024 | Nexplanon |
| Daiichi Sankyo INC. | $34.79 | 2023 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $31.90 | 2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $28.69 | 2020 | |
| Sunovion Pharmaceuticals INC. | $28.00 | 2019 | |
| Exact Sciences Corporation | $27.00 | 2025 | The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.93 | 2021-2024 | Xifaxan |
| Astellas Pharma US INC | $22.92 | 2025 | Veozah |
| Advanced Respiratory, INC | $19.06 | 2021 | |
| Genentech USA, INC. | $18.73 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.09 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.02 | 2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $16.45 | 2024 | Uzedy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Harbison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.